In renal allograft recipients, day 7 inulin clearance did not differ between IGF‑1 and placebo.
In plain wordsIn kidney transplant recipients, day 7 kidney clearance did not differ between IGF‑1 and placebo.
- Peptide
- IGF-1 (mecasermin)
- Outcome
- No significant changeDay 7 inulin clearance
- Study
n = 43
- Comparator
- Placebo
- Analysis
- Primary
- Outcome group
- Kidney function · Kidney and urinary
- Studied dose
- 100 mg/kg twice a day · subcutaneous · 6 daysAs given in this study (human).
Measurements
- Day 7 inulin clearance, mean (+/- 22)
- 21 mL/min
- IGF-1 group (N = 19)
- Day 7 inulin clearance, mean (+/- 19)
- 19 mL/min
- placebo group (N = 24)
- P value for day 7 inulin clearance comparison
- 0.67 p value
- IGF-1 group versus placebo group, day 7
- Analysed sample count for day 7 inulin clearance
- 19 patients
- IGF-1 group, day 7
- Analysed sample count for day 7 inulin clearance
- 24 patients
- placebo group, day 7
Source sentences
Inulin clearance on day 7, the primary outcome measure, was 21 +/- 22 mL/min and 19 +/- 19 mL/min in the IGF-1 (N = 19) and placebo (N = 24) groups, respectively (P = 0.67).
1 context sentence(design, population, supporting numbers)
To circumvent these confounding factors, we randomized recipients of cadaveric renal allografts to immediate (<5 hours) rhIGF-1 versus placebo therapy (100 mg/kg subcutaneously twice a day for 6 days).